Introduction {#s1}
============

Mechanisms of transcription regulation in bacteria are very well established; transcription factors bind to specific DNA to recruit RNA Polymerases (RNAP) to carry out transcription ([@bib32]; [@bib52]). In eukaryotes, however, there are additional layers of regulation such as the nucleosome structures, which can prevent RNA Polymerases including RNA Polymerase I (Pol I), RNA Polymerase II (Pol II), and RNA Polymerase III (Pol III) from productive transcription due to high binding affinity between DNA and histones. Precisely how RNA Polymerases overcome nucleosomal barriers to undergo a productive transcription elongation and how Pol II pausing is regulated remain unanswered ([@bib53]; [@bib18]; [@bib8]). In higher eukaryotes, over \~30% genes are regulated by Pol II promoter-proximal pausing ([@bib7]; [@bib28]; [@bib27]), which is resultant from nucleosome barriers at +1 position of transcription start sites ([@bib43]; [@bib41]). We recently discovered that a group of JmjC domain containing protein family including JMJD5 and JMJD7 specifically cleave histone tails and potentially generate tailless nucleosomes. The cleavage activity by JMJD5 and JMJD7 could be associated with the release of the promoter-proximal paused Pol II and may trigger Pol II into productive elongation in higher eukaryotes, such as mouse and human ([@bib25]; [@bib26]). The cleavage activity of JMJD5 on histone tails was also independently reported by another group ([@bib37]), thus cross-validating our respective discoveries.

Compared to the efficient recruitment of P-TEFb (including CDK9 and Cyclin T1) by TAT protein in human immunodeficiency virus (HIV) ([@bib31]), BRD4 is claimed to be responsible for the recruitment P-TEFb to the promoters of Pol II pausing regulated genes ([@bib16]; [@bib49]; [@bib2]). However, the binding affinity between BRD4 and P-TEFb (\~0.5 μM) ([@bib15]) is much weaker than that that of TAT and P-TEFb (\~3 nM) ([@bib44]; [@bib39]; [@bib35]), and BRD4 lacks a RNA binding motif ([@bib47]). Therefore, we hypothesize there must exist another factor to help BRD4 to recruit P-TEFb and engages in the instigation of Pol II transcription elongation. Besides the classic Bromo-domains which recognize acetylated histone tails, BRD4 contains an extra terminal domain (ET) recognizing JMJD6 ([@bib33]; [@bib19]). Incidentally, we found that JMJD6 nonspecifically binds to single stranded RNA with high affinity (\~40 nM) ([@bib13]). We propose that JMJD6 may be recruited by both BRD4 and newly transcribed RNAs from Pol II to help BRD4 recruit P-TEFb, acting analogously to that of TAT protein associating with both P-TEFb and TAR.

JMJD6 is one of the most controversial proteins in biology ([@bib40]). It was first cloned as phosphatidylserine (PS) receptor ([@bib10]), but was corrected as a nucleus expressed protein unrelated to PS ([@bib1]; [@bib6]; [@bib9]). It was later reported to contain arginine demethylase activity on histone tails ([@bib3]), hydroxylase activity on splicing factor U2AF65 ([@bib42]) and histone tails ([@bib12]), and both arginine demethylase activities on histone tails and RNA demethylase activities on 5' prime of 7SK snRNA ([@bib24]), and surprisingly PS binding ([@bib29]; [@bib51]). The exact or cognate substrate(s) of JMJD6 remains unresolved or controversial. Based on the novel protease activities of JMJD5 and JMJD7 ([@bib25]; [@bib37]; [@bib26]), the high structural similarity among catalytic cores of JMJD5, JMJD6, and JMJD7 ([@bib13]; [@bib26]), and analogous severe phenotypes among knockouts of *Jmjd5* and *Jmjd6* in mice ([@bib23]; [@bib1]; [@bib14]; [@bib30]), we hypothesized that JMJD6 may contain protease activity working on methylated arginines on some protein candidates which regulate the activity of Pol II, especially promoter-proximally paused Pol II.

It is well established that the 7SK snRNP complex primarily functions to sequester the CDK9-containing P-TEFb until stimulation ([@bib16]; [@bib49]). MePCE (methylphosphate capping enzyme) was first characterized as a component of the 7SK snRNP complex which acts as a capping enzyme on the gamma phosphate at the 5'end of 7SK RNA ([@bib17]). Furthermore, a capping-independent function of MePCE via stabilization of 7SK snRNA and facilitation in the assembly of 7SK snRNP was reported by Dr. Qiang Zhou's group ([@bib48]). Knockdown of MePCE led to destabilization of the 7SK snRNP complex in vivo ([@bib48]; [@bib38]; [@bib2]). A nonsense variant of MePCE is reported to be associated with a neurodevelopmental disorder exhibiting hyperphosphorylation of Pol II, potentially caused by enhanced activation of CDK9 complex ([@bib34]). Interestingly, one report showed that MePCE may also work in an 7SK snRNP independent manner to recruit CDK9 on a small group of genes ([@bib36]). In this report, we reveal that MePCE of the 7SK snRNP complex is a cognate substrate of JMJD6.

Results {#s2}
=======

JMJD6 has a unique structure to hold methyl-arginine {#s2-1}
----------------------------------------------------

Based on these divergent reports regarding substrates of JMJD6 ([@bib3]; [@bib42]; [@bib12]; [@bib24]; [@bib29]), we re-interrogated proposed substrates using stringent and unified criteria. As we reported previously, JMJD6 binds with high binding affinity (\~40 nM) to single stranded RNA (ssRNA) without sequence specificity ([@bib13]). However, truncation analysis showed that JMJD6 barely binds to ssRNA without the C-terminal flexible region ([@bib13]). This suggests that the C-terminal domain of JMJD6 may just serve as ssRNA binding motif and RNAs are not a substrate for the enzymatic activity of JMJD6. On the other hand, the structure of the catalytic core of JMJD6 shows some critical similarity to those of JMJD5 and JMJD7, with a negatively charged microenvironment near the catalytic center ([@bib13]; [@bib26]), suggesting positively charged substrates ([Figure 1](#fig1){ref-type="fig"}). As we reported, JMJD5 and JMJD7 specifically recognize methylarginines of histone tails *via* a Tudor-domain-like structure near the catalytic center of JMJD5, which could specifically recognize methylarginines, but not methyllysine ([@bib25]; [@bib26]). We reasoned that the similar structural features among JMJD6, JMJD5, and JMJD7 may confer a similar substrate for JMJD6 as those of JMJD5 and JMJD7. In this regard, crystals of JMJD6 without C-terminal motif (1-343) were soaked with a monomethylarginine derivative. Interestingly, four out of eight JMJD6 molecules within an asymmetric unit bound to monomethylarginine, which coordinates with Fe2+ and alpha-KG in the catalytic center similar to that of JMJD5 and methylarginines ([Figure 1](#fig1){ref-type="fig"}, [Figure 1---figure supplements 1](#fig1s1){ref-type="fig"}--[3](#fig1s3){ref-type="fig"}, [Supplementary file 1](#supp1){ref-type="supplementary-material"}). However, the methylated sidechain of arginine is located in a more open catalytic space containing negatively charged residues, compared to that of JMJD5, indicating that the pocket could hold more than one sidechain ([Figure 1A](#fig1){ref-type="fig"}). This may suggest a novel substrate recognition mode, which is different from that of JMJD5 ([@bib26]). Nevertheless, the complex structure shows several key evidences. First, JMJD6 does bind to substrates with methylarginine or possibly methyllysine or both arginine and lysine with and without methylation ([Figure 1B,C](#fig1){ref-type="fig"}). Second, the methyl group is far away from either the divalent ion or alpha-KG, suggesting JMJD6 may not act as lysine or arginine demethylases to remove methyl groups on the sidechain of either lysine or arginine. Third, peptides or proteins could be cognate substrates instead of RNA or DNA, which do not contain any positive charge with or without methylation. Fourth, the catalytic center contains analogous residues present in JMJD5 and JMJD7, suggesting a similar novel catalytic mechanism as those of JMJD5 and JMJD7 through an imidic acid as proton mediator ([Figure 1D](#fig1){ref-type="fig"}; [@bib22]; [@bib26]). This novelty is particularly exemplified by the fact that commercially available protease inhibitor cocktail (Roche) at 2x concentration cannot inhibit activities of JMJD5, JMJD6, and JMJD7. Furthermore, a comprehensive protein composition analysis using mass spectrometry ([Supplementary file 2](#supp2){ref-type="supplementary-material"}) of all purified recombinant JMJD6 samples used in the following experiments could not detect any protease contaminants.

![JMJD6 binds to monomethyl arginine (1-of-4).\
(**A**) Complex structure of JMJD6 (1--343) and monomethyl arginine (MM-Arg). Surface charges were generated using PyMOL (Action \> generate \> vacuum electrostatics \> protein contact potential[; https://pymol.org/2/](https://pymol.org/2/)). Red represents negatively-charged surface, Gray represents neutral-charged surface, and Blue represents positively-charged surface. (**B**) Omit map 2Fo-Fc electron density of MM-Arg. (**C**) Magnified view of MM-Arg in the catalytic center of JMJD6 (**D**) Coordination of elements at catalytic center.](elife-53930-fig1){#fig1}

JMJD6 cleaves MePCE {#s2-2}
-------------------

Since JMJD5 and JMJD7 make cleavage on histone tails ([@bib25]), we asked whether JMJD6 also recognizes histone tails. Interestingly, JMJD6 does in fact have activities on bulk histone in vitro ([Figure 2---figure supplement 1A](#fig2s1){ref-type="fig"}). This result may explain why two groups found that JMJD6 could reduce methylarginine containing histone tails in in vitro assays probed with antibodies ([@bib3]; [@bib24]), in which post-cleft short peptides with methylarginines cannot be recognized by antibodies in western blots. To confirm or rule out whether histone tails are cognate substrates of JMJD6, we first assessed the binding affinity between JMJD6 and histone peptides with or without arginine methylation. From fluorescence polarization binding assays, binding affinities between JMJD6 and peptides are weak and around \~150 μM ([Figure 3---figure supplement 1D,E](#fig3s1){ref-type="fig"}). Most importantly, with or without *Jmjd6*, the level of arginine methylated histones or overall histone levels does not change in MEF cells in vivo ([Figure 2---figure supplement 1B](#fig2s1){ref-type="fig"}), which is in stark contrast to those of JMJD5 and JMJD7 ([@bib25]). These data suggest that histone tails are not cognate substrates of JMJD6. Parenthetically, it is reported that JMJD6 binds to LARP7 on 7SK snRNP ([@bib45]), works on methyl cap of 5' 7SK snRNA ([@bib24]), and binds to BRD4 ([@bib33]; [@bib19]), all suggesting a close relation with the 7SK snRNP complex.

We hypothesized that JMJD6 may work on some protein component(s) of the 7SK snRNP to regulate the stability of 7SK snRNP complex. Interestingly, all protein components of the 7SK snRNP complex including MEPCE, LARP7, and HEXIM1 are drastically decreased in the MEF cells without *Jmjd6* ([Figure 2A](#fig2){ref-type="fig"}). One possibility is that all members are transcriptionally regulated by JMJD6. This could be consistent with the severe phenotype of *Jmjd6* knockouts, which results in neonatal lethality and cell growth retardation and tissue differentiation ([@bib23]; [@bib1]), suggesting that JMJD6 is a global master transcriptional regulator controlling expression of a large group of genes including components from the 7SK snRNP complex. However, our RNA-Seq data does not support direct transcriptional downregulation of 7SK snRNP complex members at mRNA level ([Supplementary file 3](#supp3){ref-type="supplementary-material"}). All of them, including MePCE, LARP7, and HEXIM1 have similar mRNA levels with or without *Jmjd6*. At the moment, the cause of this downregulation of proteins level of these components from 7SK snRNP remains unresolved and is beyond the scope of this report. However, when we introduce back JMJD6 via overexpression into MEF cells lacking *Jmjd6*, protein levels of LARP7 and HEXIM1 are rescued, whereas MePCE is undetectable ([Figure 2A](#fig2){ref-type="fig"}) or significantly reduced ([Figure 2---figure supplement 1C](#fig2s1){ref-type="fig"}). To account for this disappearance of MePCE, we hypothesized that overexpression of JMJD6 may directly target MEPCE for degradation. To confirm this hypothesis, we respectively overexpressed full-length MePCE in wild-type MEF, *Jmjd6* knockout MEF, wild-type JMJD6 overexpression in *Jmjd6* knockout MEF, and inactive mutant JMJD6 overexpression in *Jmjd6* knockout MEF. The whole cell lysates were probed with anti-MePCE antibody. Our hypothesis was vindicated with the emergence of a lower molecular weight form of MePCE in wild-type MEF and wild-type JMJD6 overexpression in *Jmjd6* knockout MEF, whereas the lower molecular weight form of MePCE was not detectable in the *Jmjd6* knockout MEF, and inactive mutant JMJD6 overexpression in *Jmjd6* knockout MEF ([Figure 2B](#fig2){ref-type="fig"}).

![JMJD6 targets MePCE for proteolysis.\
(**A**) Western blot of wild-type MEF, *Jmjd6* knockout MEF, and JMJD6 overexpression in *Jmjd6* knockout MEF probed with antibodies specific for JMJD6, Actin, and components of the 7SK snRNP complex; LARP7, HEXIM1, and MePCE. (**B**) Western blot of MePCE overexpressed respectively in wild-type MEF, *Jmjd6* knockout MEF, wild-type JMJD6 overexpression in *Jmjd6* knockout MEF, and inactive mutant JMJD6 overexpression in *Jmjd6* knockout MEF; probed with antibody specific for MePCE. (**C**) Wild-type JMJD6 titrated into full-length MePCE with N-terminal His^6^-tag. Enzymatic activity of JMJD6 is probed with anti-His^6^ antibody. (**D**) Quantification of c. (**E**) The endopeptidase activity of JMJD6 on synthesized MePCE (161-179) R171-me2s/C177S peptide. The mass spectrum is normalized to the intensity of the undigested peptide input. The peptide is assayed with wild-type JMJD6 (green), inactive mutant JMJD6 (red), or peptide alone (black). The MePCE (161-179) peptide with symmetric dimethylation on R171 and C177S mutation has a molecular weight of 2,290.57 Da. After wild-type JMJD6 cleavage between R170 and R171, the major peaks\* (black triangles) with the molecular weight of 1,243.48 Da corresponds to the N-terminal product and the molecular weight of 1,065.11 Da corresponds to the C-terminal product respectively. \*The multiple peaks are isotopic distributions, which are characteristic of MALDI-TOF.](elife-53930-fig2){#fig2}

To reproduce these in vivo results in an in vitro setting, full-length proteins linked with N-terminal His^6^-tag of MePCE and HEXIM1 were generated from insect cells and LARP7 and HEXIM2 were generated from bacteria and purified, followed by subjecting these proteins to direct in vitro enzymatic assays. Consistent with our in vivo results, JMJD6 cleaves MePCE in vitro ([Figure 2C,D](#fig2){ref-type="fig"}), but not HEXIM1, HEXIM2, nor LARP7 (data not shown). Upon cleavage of MePCE by JMJD6 in vitro, a band with molecular weight \~25 kDa was detected by antibody against His^6^-tag at the N-terminal ([Figure 2C](#fig2){ref-type="fig"}). To provide context, MePCE contains a total of 689 residues and a theoretical molecular weight of 74.4 kDa, whereas it is detected at \~90 kDa on SDS-PAGE gel due to its high content of proline residues (10.7%). We expect that the \~25 kDa fragment from N-terminal of MePCE may contain 200 residues or less due to rich proline residues within the N-terminal of MePCE (first 150 residues of MePCE contains 27 prolines, 18.0% prolines). Furthermore, our in vivo assay yielded a cleaved MePCE band with a molecular weight \~65 kDa ([Figure 2B](#fig2){ref-type="fig"}). The anti-MePCE antibody used in this assay was generated using a peptide immunogen containing residues 200--250 of MePCE. Thus, the \~65 kDa band may correspond to the cleaved C-terminal segment of MePCE containing the approximate residues 200--689.

Based on the binding of JMJD6 to methylated arginine we obtained from the complex crystal structure, we reasoned that arginine residues within approximately the first 200 residues of MePCE could contain the recognition site. Several peptide fragments including residues from 81 to 160, residues 154 to 184, and residues 187 to 244 were synthesized. Peptides of 81--160 and 187--244 did not show any cleavage when incubated with JMJD6. Peptides of 154--184 showed cleavage activity, but at levels of \<1% compared to peptide input. We attributed this low activity as a matter of insolubility and dimerization via C177 oxidation. To overcome this obstacle, a shorter peptide from residue 161 to 179 containing C177S was synthesized and subjected to enzymatic reaction under JMJD6. This peptide also contains symmetric dimethylation on R171, given that our binding data, described in the next section, suggests that this particular modification yields the highest binding affinity ([Figure 3C](#fig3){ref-type="fig"}). In line with our expectations, dominant peaks corresponding to the cleaved MePCE peptide products were detected by mass spectrometry, but not in either peptide alone or with an inactive mutant version of JMJD6 ([Figure 2E](#fig2){ref-type="fig"}).

![JMJD6 specifically binds to MePCE site containing residues 164--178 (determined via MST).\
(**A**) The binding of His-JMJD6 (1--343) to unmodified MePCE (154-184). (**B**) The binding of His-JMJD6 (1--343) to MePCE (154-184) R170-me2s. (**C**) The binding of His-JMJD6 (1--343) to MePCE (154-184) R171-me2s. (**D**) The binding of His-JMJD6 (1--343) to unmodified Histone 3 (1-21). (**E**) The binding of His-JMJD6 (1--343) to Histone 3 (1-16) R2-me2s. (**F**) The binding of His-JMJD6 (1--343) to C-peptide (57-87). (**G**) Electrostatic interactions between JMJD6 (1--343) and MePCE (164-178) determined by YASARA Energy Minimization server are highlighted in yellow dotted circles and catalytic center is highlighted in magenta dashed circle. (**H**) Western blot of wild-type 293 T cells (left lane) and MePCE knockout 293 T cells (right lane) probed with antibody specific for MePCE. (**I**) Western blot of MePCE knockout 293 T cells overexpressing C-terminal His^6^-tagged wild-type MePCE (left lane) or C-terminal His^6^-tagged mutant MePCE (right lane), respectively, probed with antibody specific for His^6^-tag. (**J**) Western blot of wild-type JMJD6 overexpression in *Jmjd6* knockout MEF cells overexpressing C-terminal His^6^-tagged wild-type MePCE (left lane) or C-terminal His^6^-tagged mutant MePCE (right lane), respectively, probed with antibody specific for His^6^-tag.](elife-53930-fig3){#fig3}

JMJD6 specifically recognizes methylarginine within MEPCE {#s2-3}
---------------------------------------------------------

To determine the binding affinity between JMJD6 and the newly discerned MePCE proteolysis site, Microscale Thermophoresis (MST) assay was performed using catalytic core of JMJD6 (1--343) titrated with the MePCE (154-184) peptide exhibiting: no modification ([Figure 3A](#fig3){ref-type="fig"}), R170-me2s ([Figure 3B](#fig3){ref-type="fig"}), or R171-me2s ([Figure 3C](#fig3){ref-type="fig"}). The highest binding affinity was exhibited by the MePCE (154-184)-R171-me2s peptide with Kd = 159 ± 77 nM, followed by the peptide containing no modification with Kd = 471 ± 292 nM, and lastly the peptide with R170-me2s with Kd = 568 ± 316 nM. Fluorescence polarization assays were used to cross-validate the Kd values obtained via MST above, all of which respectively fell within the margin of error ([Figure 3---figure supplement 1A,B,C](#fig3s1){ref-type="fig"}). These data suggest that methylation on R171 enhances binding nearly 3-fold compared to no modification, whereas methylation on R170 diminishes binding marginally. Whether or not these particular methylations occur in vivo is yet to be explored. Interestingly, the YASARA Energy Minimization Server developed by Dr. Kevin Karplus' group yielded a theoretical model that positions R171 in the identical position to the monomethyl-arginine observed in our crystal model ([Figure 3---figure supplement 2A](#fig3s2){ref-type="fig"}; [@bib21]). Furthermore, the energy-minimized model displayed eight separate charge-charge interactions between JMJD6 and MePCE ([Figure 3G](#fig3){ref-type="fig"}). Although a *bona fide* complex structure is preferred, this computational model is in excellent agreement with all our findings and provides a coherent justification for the experimentally observed high binding affinities between JMJD6 and MePCE. To compare the abovementioned binding affinities to that of JMJD6 and histone tails, as other groups have previously purported, the identical MST assay was performed using peptides derived from Histone 3 (1-21) containing no modification (H3) ([Figure 3D](#fig3){ref-type="fig"}), Histone 3 (1-16)-R2-me2s (H3R2me2s) ([Figure 3E](#fig3){ref-type="fig"}), and C-peptide (57-87) as a negative control ([Figure 3F](#fig3){ref-type="fig"}). For the Histone three peptides, low binding affinity was exhibited with Kd = 77 ± 34 μM for H3 peptide and Kd = 98 ± 14 μM for H3R2me2s peptide. No meaningful binding was observed for the C-peptide ([Figure 3F](#fig3){ref-type="fig"}). To verify the authenticity of the above model and confirm our proposed cleavage site of JMJD6 within MePCE, we generated an MePCE knockout 293 T cell line ([Figure 3H](#fig3){ref-type="fig"}) and respectively overexpressed C-terminal His^6^-tagged wild-type MePCE or C-terminal His^6^-tagged mutant MePCE, which replaced -RRRR- to -AAAA- at the cleavage site. Interestingly, when probed with anti-His^6^ antibody in a western blot, wild-type MePCE generates two bands of MePCE ([Figure 3I](#fig3){ref-type="fig"}, left lane), consistent with [Figure 2B](#fig2){ref-type="fig"}, whereas the mutant version does not ([Figure 3I](#fig3){ref-type="fig"}, right lane), suggesting that this site is the authentic cleavage site for JMJD6. To further confirm these results, we introduced the two variants of MePCE back to the JMJD6 overexpressing MEF cell line in *jmjd6* knockout background. Once again consistent with [Figure 2B](#fig2){ref-type="fig"}, two major bands show up with the wild-type MePCE ([Figure 3J](#fig3){ref-type="fig"}, left lane), whereas only one major band and one faint band show up with the mutant MePCE ([Figure 3J](#fig3){ref-type="fig"}, right lane). This data provides another solid evidence of the cleavage site within MePCE by JMJD6. To further verify our proposed role of JMJD6 on MePCE, the mutant MePCE containing N-terminal His^6^-tagged was expressed in insect cells and purified for an in vitro assay. The native form of MePCE generates a small band ([Figure 3---figure supplement 2B](#fig3s2){ref-type="fig"}), consistent with [Figure 2C](#fig2){ref-type="fig"}, whereas the mutant MePCE does not generate any additional band ([Figure 3---figure supplement 2C](#fig3s2){ref-type="fig"}). Taken together, we propose that JMJD6 is the cognate protease of MePCE and cleaves at the R171 site within MePCE.

Knockout of *Jmjd6* leads to down-regulation of Ser2p-CTD of pol II {#s2-4}
-------------------------------------------------------------------

We previously reported that cleavage of histone tails by JMJD5 and JMJD7 could lead to tailless nucleosomes, which are unstable and are more readily overcome by Pol II during transcription ([@bib25]; [@bib26]). What happens when MePCE is cleaved? Does MePCE cleavage mediate P-TEFb to be released from the 7SK snRNP complex, allowing P-TEFb to be recruited to CTD of Pol II, and then to phosphorylate Ser2-CTD of Pol II? Nuclear extracts from both wild-type MEFs, *Jmjd6* knockout MEFs and JMJD6 overexpression in *Jmjd6*-deficient MEFs were subjected to investigation as to the level of Ser2p-CTD of Pol II. Consistent with all our current and previous findings, Ser2p-CTD of Pol II is drastically reduced (\~80%) in MEF cells without *Jmjd6*, despite CDK9 levels remaining unchanged, suggesting that Ser2p-CTD of Pol II is regulated by JMJD6 ([Figure 4A,B](#fig4){ref-type="fig"}). A question raised here is whether the drop of active Pol II (Ser2p-CTD) is related to the protease activity of JMJD6 toward the CDK9-sequestering role of MePCE. Therefore, the MePCE knockout cell line was investigated for its effect on Pol II. To our great satisfaction, Pol II Ser2p-CTD is dramatically increased in 293 T cells with MePCE knockout ([Figure 4C](#fig4){ref-type="fig"}, right lane) compared to the wild-type ([Figure 4C](#fig4){ref-type="fig"}, left lane). Of interest, [@bib36] showed that CDK9 interacts with the N-terminal region of MePCE (1-400)). We found a very similar JMJD6 cutting site around residues 363--367 (-RKRRR-) compared the site we characterized around residues 167--172 (-KRRRR-). If JMJD6 also cuts this site as well, it seems that MePCE may act as an anchor site for CDK9 on 7SK snRNP complex. It is an interesting topic that requires further investigation.

![JMJD6 regulates Pol II Ser2-CTD phosphorylation.\
(**A**) Western blot of wild-type MEF, *Jmjd6* knockout MEF, and JMJD6 overexpression in *Jmjd6* knockout MEF probed with antibodies specific for Pol II CTD, Pol II ser2p-CTD, CDK9, and Actin. (**B**) Quantification of Pol II Ser2p-CTD on a. (\*\*, p\<0.01; NS, not significant) (**C**) Western blot of wild-type 293 T cells and *MePCE* knockout 293 T cells probed with antibodies specific for for Pol II CTD, Pol II ser2p-CTD, and Actin. (**D**) Model of JMJD6 cleavage of MePCE within the 7SK snRNP complex. A representative surface charge model of JMJD6 with unstructured C-terminal tail highlights respective JMJD6 interaction sites with MePCE, BRD4, and ssRNA in magenta dashed circles. (**E**) ssRNA-bound JMJD6 and acetylated H3/H4-bound BRD4 in conjunction (black dotted circle) bridges P-TEFb to paused Pol II. (**F**) TAR-bound TAT (black dotted circle) bridges P-TEFb to paused Pol II.](elife-53930-fig4){#fig4}

The totality of our results is consistent with the critical role of JMJD6 in embryonic development, which is neonatal lethal without *Jmjd6* ([@bib23]; [@bib1]). It explains why growth of MEF cells without *Jmjd6* is severely compromised, similar to those without either *Jmjd5* or *Jmjd7* ([@bib25]). This data suggests not only that JMJD6's cleavage of MePCE is essential for P-TEFb to be released from the 7SK snRNP complex and ultimately the phosphorylation of Ser2-CTD of Pol II, but also further cross-confirms that a species of Ser2p-CTD of Pol II is indeed generated by CDK9. The content of Ser2p-CTD of Pol II is recovered when JMJD6 is re-expressed ([Figure 4A,B](#fig4){ref-type="fig"}), suggesting the direct relation of JMJD6 and phosphorylation of Ser2-CTD of Pol II in vivo. When these results are aggregated with previously published reports, whereby (1) JMJD6 exhibits strong binding affinity to nonspecific ssRNA as we previously reported ([Figure 4D](#fig4){ref-type="fig"}; [@bib13]), (2) JMJD6 associates with BRD4 as reported by others ([Figure 4D](#fig4){ref-type="fig"}; [@bib33]; [@bib19]), and (3) JMJD6 digests MePCE so as to disrupt the overall stability of 7SK snRNP complex as highlighted in this report ([Figure 4D](#fig4){ref-type="fig"}), a model of P-TEFb transcription regulation unique to higher eukaryotes can be generated: JMJD6 binds to 20--50 nt newly transcribed 5' prime end of ssRNAs of initiated Pol II of any stimulating genes. The association between BRD4 and JMJD6 allows BRD4 to bring P-TEFb (CDK9) to close proximity of CTD of Pol II, allowing for Ser2-CTD phosphorylation ([Figure 4E](#fig4){ref-type="fig"}). Remarkably, this recruitment of P-TEFb by JMJD6, with the assistance of BRD4, is similar to that of TAT protein hijacking P-TEFb complex after associating with TAR transcript to trigger the expression of HIV retroviral genome ([Figure 4F](#fig4){ref-type="fig"}; [@bib31]; [@bib53]; [@bib2]). Here, our observation regarding the direct relation of JMJD6 and level of Ser2p-CTD of Pol II in vivo is corroborated by Liu et al.'s report, in which 7SK snRNP complex pulled-down through HEXIM1 antibody from HEK293 cells could be disrupted by JMJD6 in vitro, as indicated by the decrease in CDK9 levels ([@bib24]), thus strongly supporting our proposed role of JMJD6 as a direct disruptor of the 7SK snRNP complex.

Discussion {#s3}
==========

It took us nearly two decades to address the structure and function of JMJD6 since it was first cloned ([@bib10]). During the long journey, based on the conserved structure of JmjC domain containing family, we pioneered in characterizing the catalytic core of JMJD2 subfamily, which turned out to be a novel lysine demethylase ([@bib4]; [@bib46]; [@bib5]). We then solved the structure of JMJD6 with the help of a monoclonal antibody and discovered its unique ssRNA binding property almost a decade ago ([@bib13]). However, the exact function and its cognate substrate remained a mystery, though several groups claimed variety of enzymatic activities and substrates in past two decades ([@bib3]; [@bib42]; [@bib12]; [@bib24]). The accidental discoveries of novel protease activities of JMJD5 and JMJD7 by our group prompted the exploration of potential protease activity of JMJD6 ([@bib25]; [@bib26]). The report by [@bib24] helped us to narrow down the potential cognate substrate within the 7SK snRNP complex. Reports of arginine demethylase activity ([@bib3]; [@bib24]) helped us to focus on methylated arginine as the potential cleavage sites. Thanks to these reports, we identified MePCE to be the cognate substrate of JMJD6, as well as the potential cleavage site. Numerous lines of evidence from our current discoveries and other publications corroborates the authenticity of this conclusion: First, JMJD6 is specifically associated with BRD4 through the ET domain ([@bib33]; [@bib19]), while BRD4 is very well established to recruit P-TEFb to paused Pol II ([@bib49]; [@bib50]). Second, JMJD6 could disrupt the 7SK snRNP complex in vitro as reported by [@bib24]. Third, our current discoveries showed that JMJD6 cleaves MePCE of the 7SK snRNP complex. Fourth, our previous discovery of JMJD6's interaction with non-specific ssRNA bridges JMJD6 to the initiated Pol II which generates 20--50 nt long ssRNA ([@bib13]).

The findings that JMJD5 and JMJD7 are in fact proteases was highly unexpected, and required multiple lines of evidence pursued with great scrutiny. It is quite extraordinary that a very conserved Jumonji domain containing hydroxylase family should contain a subfamily which evolutionarily adopted distinctive protease activities, as well as exhibit several unexpected novelties including the catalysis mechanism involving imidic acid and both endopeptidase and exopeptidase activities ([@bib25]; [@bib26]). Indeed, recombinant proteins derived from bacteria have a high chance of contamination by bacterial proteases, although we exhausted innumerable means to exclude the possibility of contamination in our assays ([@bib25]; [@bib26]). In this report, the novel protease activity of JMJD6, which cleaves *before* the methylated arginine, is remarkably distinct to the cleavage *after* the methylated arginine mediated by JMJD5 and JMJD7 ([@bib25]; [@bib26]). This important piece of evidence supports the claim of JMJD5 and JMJD7 as proteases. It is highly improbable that one batch of proteins we purified was contaminated by one type of undiscovered protease(s) (cleavage after methylated arginine for JMJD5 and JMJD7) while another batch of proteins was contaminated by a different type of undiscovered protease(s) (cleavage before methylated arginine for JMJD6), all which respectively have substrate specificity matching the expected biological profiles of JMJD5/6/7.

Based on our current discoveries, we may derive a novel transcription regulation pathway for genes regulated by promoter-proximal pausing Pol II. First, upon stimulation of cells, signals will reach specific transcription factors through signal transduction pathways. With modification or with the help of other partner molecules, these transcription factors bind to enhancers close to the paused Pol II. These transcription factors will recruit P300/CBP with the help of H3K4(me1) at enhancer regions, which in turn acetylates H3 and/or H4 on the same nucleosome bound by P300/CBP through association with H3K4(me1) to generate acetylated H3 and/or H4 ([Figure 5A](#fig5){ref-type="fig"}). Next, BRD4 is recruited to acetylated H3 and/or H4, and in turn engages with JMJD6 and the initiated Pol II complex. JMJD6 specifically cleaves MePCE of the 7SK snRNP complex so as to release the P-TEFb complex containing CDK9 ([Figure 5B](#fig5){ref-type="fig"}). Finally, JMJD6 and BRD4 brings P-TEFb to close proximity of CTD of Pol II through super elongation complex. P-TEFb (CDK9) then phosphorylates Ser2-CTD of Pol II ([Figure 5C](#fig5){ref-type="fig"}).

![Model of P-TEFb release from 7SK snRNP complex.\
(a.) Pol II is initiated at the TSS and remains in the paused state until further stimulation. Transcription factors and H3K4me recruits p300/CBP, which acetylates and generates H3ac and/or H4ac. (**b**) H3ac and/or H4ac recruits BRD4, which associates with 7SK snRNP/P-TEFb complex and JMJD6. JMJD6 associates with ssRNA from Pol II. JMJD6 digests MePCE to disrupt the 7SK snRNP complex to release P-TEFb (CDK9). (**c**) BRD4/JMJD6 brings CDK9 in close proximity of CTD of Pol II. CDK9 phosphorylates Ser2 motifs on CTD of Pol II.](elife-53930-fig5){#fig5}

Materials and methods {#s4}
=====================

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\                Designation                                                                 Source or reference                     Identifiers             Additional\
  (species) or resource                                                                                                                                                    information
  ---------------------------- --------------------------------------------------------------------------- --------------------------------------- ----------------------- ----------------------------------------------------------------
  Cell line\                   JMJD6 KO cell on MEF background                                             [@bib1]                                                         Cell line from Dr. Andreas Lengeling lab
  (*M. musculus*)                                                                                                                                                          

  Cell line\                   JMJD6 Re-expression cell line on the JMJD6 KO background                    This paper                                                      MSCV-JMJD6 transduced JMJD6 KO cell
  (*M. musculus*)                                                                                                                                                          

  Cell line (*Homo-sapiens*)   27--13 MEPCE KO cell on the HEK293 background                               This paper                                                      Cell line from Drs. Yuhua Xue lab

  Cell line\                   MEPCE Re-expression cell line on the MEPCE KO cell line 27--13 background   This paper                                                      MSCV-MEPCE with c-terminal 6\*His tag transduced MEPCE KO cell
  (*Homo-sapiens*)                                                                                                                                                         

  Antibody                     Rabbit polyclonal Phospho-Serine 2 CTD Pol II                               Nat Struct Mol Biol 15, 71--78 (2008)   Dr. David Bentley Lab   WB (1:2000)

  Antibody                     Rabbit polyclonal CTD Pol II antibody                                       Nat Struct Mol Biol 15, 71--78 (2008)   Dr. David Bentley Lab   WB (1:2000)

  Antibody                     Mouse monoclonal JMJD6 antibody                                             Santa Cruz Biotechnology                sc-28348                WB (1 µg/ml)

  Antibody                     Rabbit polyclonal MEPCE antibody                                            Bethyl Laboratories Inc                 A304-184A               WB (1:2000)

  Antibody                     Rabbit polyclonal\                                                          Novus                                   NBP2-34858              WB (1:2000)
                               MEPCE antibody                                                                                                                              

  Antibody                     Rabbit polyclonal LARP7 antibody                                            Abcam                                   ab-134757               WB (1:2000)

  Antibody                     Mouse monoclonal HEXIM1 antibody                                            Santa Cruz Biotechnology                sc-390059               WB (1 µg/ml)

  Antibody                     Mouse monoclonal actin antibody                                             Santa Cruz Biotechnology                sc-8432                 WB (1 µg/ml)

  Antibody                     Mouse monoclonal CDK9 antibody                                              Santa Cruz Biotechnology                sc-13130                WB (1 µg/ml)

  Antibody                     Mouse monoclonal His-probe antibody                                         Santa Cruz Biotechnology                sc-53073                WB (1 µg/ml)
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Protein expression and purification {#s4-1}
-----------------------------------

The cDNA corresponding to gene of wild-type JMJD6 (1--343), inactive mutant JMJD6 (1--343) H187A/D189A/H273A/K204A/N287A, HEXIM2, and LARP7 was cloned into a pET28a vector containing an N-terminal His^6^ tag. The DNA corresponding to gene of JMJD6 (1--403) wild-type was cloned into a pGEX vector containing an N-terminal GST tag and TEV linker. All proteins were expressed in Rosetta (DE3) *Escherichia coli* cells. All cell cultures were grown to A~600~ value equal to about 1.0 and induced with a final concentration of 1.0 mM isopropyl 1-thio-β-D-galactopyranoside overnight at 16°C. Cells were resuspended in nickel-binding buffer (50 mM Tris-HCl, pH8.0, 1M NaCl, 1 mM PMSF) and lysed using a sonicator (Fisher Scientific Sonic Dismembrator Model 500) at 35% power, 10 s ON, 5 s OFF, for 20 min. The lysate was centrifuged at 16,000 rpm at 4°C for 30 min. The supernatant corresponding to His-JMJD6 (1--343) was loaded to 7 mL of Ni-NTA resin (GE Healthcare), washed with nickel-binding buffer containing 20 mM imidazole, and eluted with nickel-binding buffer containing 500 mM imidazole. The supernatant corresponding to GST-tev-JMJD6 (1--403) was loaded to 7 mL of glutathione agarose resin (Thermo Scientific), washed with nickel-binding buffer, and eluted with nickel-binding buffer containing 30 mM glutathione. All eluted JMJD6 products were concentrated and purified on a superdex 200 10/300 GL column (GE Healthcare) previously equilibrated with nickel-binding buffer containing 15 mM β-mercaptoethanol. The cDNA fragment encoding full-length wild-type MePCE with an N-terminal His^6^-tag, full-length mutant MePCE (R169D/R170N/R171D/R172N) with an N-terminal His^6^-tag, and HEXIM1 with an N-terminal His^6^-tag was cloned under control of the polyhedrin promoter into a previously described baculovirus transfer plasmid ([@bib20]). Recombinant virus was made by co-transfection into SF9 insect cells (Invitrogen) of the plasmid and BacVector3000 baculovirus DNA (Novagen) using the calcium phosphate co-precipitation method. High titer virus stock was prepared by infection of SF9 insect cells. Wild-type MePCE, mutant MePCE, and HEXIM1 protein was produced by infection of High Five insect cells (Invitrogen) at high multiplicity of infection. Four days later, the cells were lysed by sonication in nickel-binding buffer. Lysates were cleared by centrifugation (20,000 rpm, 60 min) and proteins were purified from the supernatant using 7 mL of Ni-NTA resin (GE Healthcare). The protein was eluted from the column with nickel-binding buffer containing 500 mM imidazole.

Crystallization, Data Collection, structural determination, and refinement of JMJD6 {#s4-2}
-----------------------------------------------------------------------------------

His-JMJD6 (1--343) was crystallized by vapor diffusion in sitting drops with 0.1M sodium citrate pH 5.6, 1.0M ammonium phosphate monobasic at 8°C. The crystals were soaked in soaking buffer; 0.1M sodium citrate pH 5.6, 1.0M ammonium phosphate monobasic, 10 mM mono-methyl arginine, 3.75 mM αKG, 3.75 mM Iron(II) sulfate. For data collection, His-JMJD6 (1--343) crystals were transferred to a cryo-protecting buffer (soaking buffer supplemented with 25% glycerol (v/v)) and frozen in liquid nitrogen. All data used in structure solving and refinement were collected on a beam line 4.2.2 (MBC-ALS) at the Advanced Light Source (Berkeley, ALS, USA). Data were integrated and scaled using the HKL2000 suite of programs. Structural determination and refinement results are shown in [Supplementary file 1](#supp1){ref-type="supplementary-material"}.

Western blot analysis {#s4-3}
---------------------

To analyze protein levels, wild-type MEF, *Jmjd6* knockout (KO) MEF, wild-type JMJD6 overexpression in *Jmjd6* KO MEF, inactive mutant JMJD6 overexpression in *Jmjd6* KO MEF, wild-type MePCE overexpression in above four MEF cell lines, mutant MePCE (R169A/R170A/R171A/R172A) overexpression in wild-type JMJD6 overexpression in *Jmjd6* KO MEF, wild-type MePCE with a C-terminal His^6^ tag overexpression in *MePCE* KO 293T, and mutant MePCE (R169A/R170A/R171A/R172A) with a C-terminal His^6^ tag overexpression in *MePCE* KO 293 T cells were grown on 10 cm plates to be harvested and lysed using a standard RIPA buffer mixed with cOmplete Protease inhibitor cocktail (Roche). MEFs were generated from *Jmjd6^tm1.1Gbf^* knockout mice as previously described ([@bib1]; [@bib11]). Total cellular extracts in the presence of a protein standard (Bio-rad) were resolved by 8--12% gradient SDS-PAGE and transferred to a 0.22 μm nitrocellulose membrane and incubated with specific antibodies overnight at 4°C. Antibodies used in this investigation were: Anti-JMJD6 (Santa Cruz Biotechnology, sc-28348), Anti-LARP7 (Abcam, ab-134757), Anti-HEXIM1 (Santa Cruz Biotechnology, sc-390059), Anti-MePCE (Bethyl Laboratories Inc, A304-184A), Anti-Actin (Santa Cruz Biotechnology, sc-8432), Anti-His (Santa Cruz Biotechnology, sc-53073), Anti-Pol II CTD (Gift from Dr. David Bentley), Anti-Pol II Ser2p-CTD (Gift from Dr. David Bentley), and Anti-CDK9 (Santa Cruz Biotechnology sc-13130).

In vitro MePCE cleavage assay {#s4-4}
-----------------------------

Full-length MePCE protein with N-terminal His-tag, mixed with EDTA-free cOmplete protease inhibitor (Roche), αKG, Zn^2+^, and HEPES pH 6.5, was titrated with recombinant wild-type JMJD6 and placed in 37°C for 2 hr. The reaction was subject to western blot analysis using monoclonal anti-His antibody (Santa Cruz Biotechnology, sc-53073). The reaction was reproduced in two separate experiments and the blot bands were quantified using ImageJ.

Mass spectrometry {#s4-5}
-----------------

MePCE (161-179) R171-me2s/C177S peptide, mixed with EDTA-free cOmplete protease inhibitor (Roche), αKG, Zn^2+^, and HEPES pH 6.5, was treated with recombinant wild-type JMJD6, inactive mutant JMJD6, or peptide alone and placed in 37°C for 2 hr. 1 μL of reaction sample is mixed with 1 μL of a-cyano-4-hydroxycinnamic acid (10 mg/ml in 50% ACN, 0.1% TFA). The mixture is spotted on the MALDI target and allowed to air dry. The sample is analyzed by a Microflex-LRF mass spectrometer (Bruker Daltonics, Billerica, MA) in positive ion reflector mode. External calibration is done using a peptide calibration mixture (4 to 6 peptides) on a spot adjacent to the sample. The raw data is processed in the FlexAnalysis software (version 3.4.7, Bruker Daltonics) and exported in mzXML format. The mzXML files were analyzed on ProteoWizard. Data points were normalized to the intensity of the undigested peptide input and plotted on SigmaPlot v11.0. The reaction was reproduced in three separate experiments.

Fluorescence polarization experiment {#s4-6}
------------------------------------

Given the known structure of JMJD6, where aromatic residues are present in close proximity to the binding pocket (Y131, F133, W174, W272), the following tryptophan fluorescence assay was deemed suitable for characterizing various peptide binding activity. All the regular and methylated peptides were synthesized by AnaSpec Inc (Histone 3) or Peptide 2.0 Inc (MePCE). 5 μM JMJD6 (1--343) was titrated and equilibrated with fixed concentrations of each peptide respectively, incubated at 25°C for 30 min between each titration intervals, and subject to fluorescence measurement. The buffer used in the fluorescence quenching assay was 100 mM NaCl, 20 mM Tris-HCl pH 6.5, and 0.05% Tween-20. The excitation wavelength of 280 nm and the emission wavelength of 342 nm was used for data collection and recorded with a Fluoromax-3 spectrometer. The titration samples were prepared and analyzed in parallel as duplicates, triplicates, or quadruplicates. All values at different titration points were compiled, normalized against the maximum value obtained prior to titration and averaged. The error bars indicate the normalized minimum and maximum values at any given titration point. The K~D~ for each peptide was calculated by fitting to a four parameter sigmoidal dose-response curve with SigmaPlot v11.0.

Microscale thermophoresis (MST) experiment {#s4-7}
------------------------------------------

His-JMJD6 (1--343) labeled with fluorescent NT-647 dye at a constant concentration of 100 nM was mixed with sixteen serial dilutions (\~1.5 nM--300 μM) of peptides derived from MePCE (154-187), MePCE (154-184) R170-me2s, MePCE (154-184) R171-me2s, Histone 3 (1-21), Histone 3 (1-16) R2me2s, C-peptide (57-87). C-Peptide (57-87) was used as a negative control. MST experiment was performed using Monolith NT.115 (NanoTemper Technologies). His-JMJD6 (1--343) was titrated with peptides in PBS-T buffer (137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4, and 0.05% Tween-20). The change in the fluorescence of bound and unbound labeled His-JMJD6 (1--343), ΔF, is indicative of the peptide binding. Plotting ΔF vs. peptide concentration facilitated the generation the dissociation curves, computed by the NTP program. The K~D~, reflecting the affinity of each of the peptides for His-JMJD6 (1--343), was obtained. The error bars indicate the normalized minimum and maximum values at any given titration point. Each experiment was performed in triplicate or quadruplicate.

Modeling of JMJD6(1--343)-MePCE(164-178) interaction {#s4-8}
----------------------------------------------------

Crystal structure of JMJD6 (1--343) monomer (PDB:6MEV) sans methylarginine was used as the template to build in residues corresponding to MePCE (164-178) near the catalytic center of JMJD6 in PyMol. No regard for clashes, bonds, or optimization was considered. Structure was exported in. pdb format and uploaded to YASARA energy minimization server (<http://www.yasara.org/minimizationserver.htm>) using default parameters ([@bib21]). Energy-minimized output model was converted to. pdb format and the MePCE (164-178) residues were minimally adjusted in PyMol to superimpose R171 of MePCE with the methylarginine observed in the crystal structure (PDB:6MEV).

Quantification of pol II Ser2p-CTD {#s4-9}
----------------------------------

Western blot of Pol II Ser2p-CTD and unmodified Pol II CTD in wild-type MEF, *Jmjd6* knockout (KO) MEF, or wild-type JMJD6 overexpression in *Jmjd6* KO MEF was reproduced in four separate experiments. All blot bands were quantified using ImageJ and the band intensity of Pol II Ser2p-CTD was normalized against the band intensity of unmodified Pol II CTD in each respective cell lines. The band intensity of each replicate was normalized against the Pol II Ser2p-CTD level in wild-type MEF, then averaged. The error bars indicate one standard deviation to the observed mean. The P-value was obtained using a paired t-test.

RNA-Seq {#s4-10}
-------

RNAs from wild type MEF cells, MEF cells with *Jmjd6* knockout, and MEF cells with JMJD6 overexpression cells in *Jmjd6* knockout background, respectively, were extracted with Trizol reagent (ThermoFisher Scientific). The extracted RNAs were then sent to Quick biology (Quick Biology, Pasadena) for further mRNA purification using oligo-d(T) beads. The purified mRNA was then used to build a mRNA library. Mouse Genome mm10 was used as the reference.
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Additional files {#s6}
================

###### Crystallographic statistics of complex structure of JMJD6 and a methylated arginine.

###### Protein Composition Analysis via Mass Spectrometry.

Bacteria expressed and purified JMJD6 are subjected to mass spectrum analysis, all potential contaminated trace protein candidates are listed. No known protease candidate is identified from the list.

###### Total RNA-seq reads of wild-type MEF, JMJD6 knockout MEF, and JMJD6 overexpressed in JMJD6 KO background MEF.

Data availability {#s7}
=================

Diffraction data have been deposited in PDB under the accession code 6mev, All data generated or analysed during this study are included in the manuscript and supporting files.

The following dataset was generated:
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In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.

**Acceptance summary:**

Your findings on the novel role of JMJD6 on cleaving MePCE and consequently regulating gene transcription are interesting and exciting.

**Decision letter after peer review:**

\[Editors' note: the authors submitted for reconsideration following the decision after peer review. What follows is the decision letter after the first round of review.\]

Thank you for choosing to send your work, \"JMJD6 Cleaves MePCE to Release P-TEFb\", for consideration at *eLife*. Your article has been reviewed by two peer reviewers, including Zhiguo Zhang as the Reviewing Editor and Reviewer \#1, and the evaluation has been overseen by a Senior Editor. Although the work is of interest, we regret to inform you that the findings at this stage are too preliminary for further consideration at *eLife*.

Specifically, both reviewers agreed that the study is reporting interesting findings and contained both structural and biochemical data. However, both reviewers thought that additional experiments are needed to support the proposed model, so we decided to reject the manuscript at the current form. However, we would be happy to reconsider the manuscript if you could address major concerns listed from 1 to 4 experimentally as well as other concerns with the text.

*Reviewer \#1:*

In this manuscript, Lee et al. studied the role of JMJD6 in the release of P-TEFb, a protein involved in the regulation of RNA polymerase II activity. Several activities including histone lysine/arginine demethylase activity were described for JMJD6. Based on the previous findings from the PI\'s laboratory, Lee et al. show that JMJD6 has a proteolytic activity, likely targeting MePCE, a core component of 7SK snRNP complex. First, based on the structural studies, Lee et al. found that JMJD6 bound methylated arginine. The binding configuration between methylated arginine and JMJD6 likely rules out the possibility that JMJD6 acts as an arginine demethylase. Instead, JMJD6 functions like JMJD5 and JMJD7 as a protease. Based on the in vitro binding and enzymatic assays as well as in vivo analysis the degradation products of MePCE, they show that MePCE instead of histones is a substrate of JMJD6. Overall, this study is interesting and most of data are convincing. I have following suggestions to improve the manuscript.

1\) More data is needed to support the model presented in Figure 3G. for instance, mutations at key residues shown in this figure in MePCE should be made and test how JMJD6 cleavages the mutant form MePCE in vitro and in vivo.

2\) To support the model of Figure 5, MePCE mutants that cannot be digested by JMJD6 especially R171 should be used: how do MePCE mutants that cannot be digested by JMJD6 affect Pol2 phosphorylation?

*Reviewer \#3:*

This manuscript reports an interesting finding that JMJD6 contains protease activity that is methyl-arginine guided and targets MePCE, a component of the 7SK snRNP, in vitro. The strength of the manuscript is the nice biochemical study of in vitro expressed MePCE and JMJD6 in Figure 2. However, this finding remains largely disjointed from the rest of the manuscript, which left me overall a bit underwhelmed especially with respect to the biological data.

1\) The structure of JMJD6 binding to a monomethyl-arginine derivative in Figure 1. Later in Figure 3, dimethyl-arginine in MePCE is critical for binding and cleavage. A structure of a dimethyl-arginine-MePCE peptide would be much more informative.

2\) The finding that most inhibitory components of the 7SK snRNP including MePCE itself are positively regulated by JMJD6 via an unknown mechanism is confusing (Figure 2A). This introduces a huge confounding element that remains unexplained but could have direct influence on the phenotype in Figure 4.

3\) The model in Figure 4 does not mention MePCE cleavage and is exclusively composed of elements from other publications featuring the recruitment of JMJD6 via RNA and binding to BRD4. No experimental data in the manuscript supports this model. In fact, this model can function without MePCE cleavage.

4\) The recognition and cleavage site mapping in MePCE is nice but would be even nicer if supported by mutagenesis of full-length MePCE and testing in vitro and after overexpression in cells.

5\) The S2P phenotype in Figure 4 is not the cleanest and should be quantified in multiple experiments. No evidence links this phenotype to the described cleavage of MePCE. In fact, a recent paper by Shelton et al., 2018 questions that MePCE is indeed part of the inhibitory 7SK snRNP but activates P-TEFb in a BRD4-independent manner. This paper should be discussed and the finding should be linked to MePCE cleavage, i.e. by looking at 7SK snRNP large complex levels in the JMJD6 KO cells.

\[Editors' note: further revisions were suggested prior to acceptance, as described below.\]

Thank you for resubmitting your work entitled \"JMJD6 Cleaves MePCE to Release P-TEFb\" for further consideration by *eLife*. Your revised article has been reviewed by two peer reviewers, including Zhiguo Zhang as the Reviewing Editor and Reviewer \#1, and the evaluation has been overseen by Jessica Tyler as the Senior Editor.

The manuscript has been improved but there are some remaining issues that need to be addressed before acceptance, as outlined below:

1\) Please edit some minor writing issues.

2\) Please provide statistical analysis for Figure 4B and include MeCPE in their model in Figure 4D (as you are missing the point of the paper by not highlighting the main finding -\> JMJD6 cleaves MeCPE and activates P-TEFb in their model.)

10.7554/eLife.53930.sa2

Author response

\[Editors' note: the authors resubmitted a revised version of the paper for consideration. What follows is the authors' response to the first round of review.\]

> Reviewer \#1:
>
> \[...\] Overall, this study is interesting and most of data are convincing. I have following suggestions to improve the manuscript.

*1) More data is needed to support the model presented in Figure 3G. for instance, mutations at key residues shown in this figure in MePCE should be made and test how JMJD6 cleavages the mutant form MePCE* in vitro *and* in vivo.

Please see our response to reviewer \#3, comment \#3.

> 2\) To support the model of Figure 5, MePCE mutants that cannot be digested by JMJD6 especially R171 should be used: how do MePCE mutants that cannot be digested by JMJD6 affect Pol2 phosphorylation?

We have added data in Figure 3 and Figure 4 to address this question (see our response to reviewer \#3, comment \#3.

> Reviewer \#3:
>
> *This manuscript reports an interesting finding that JMJD6 contains protease activity that is methyl-arginine guided and targets MePCE, a component of the 7SK snRNP,* in vitro*. The strength of the manuscript is the nice biochemical study of* in vitro expressed MePCE and JMJD6 in Figure 2. However, this finding remains largely disjointed from the rest of the manuscript, which left me overall a bit underwhelmed especially with respect to the biological data.
>
> 1\) The structure of JMJD6 binding to a monomethyl-arginine derivative in Figure 1. Later in Figure 3, dimethyl-arginine in MePCE is critical for binding and cleavage. A structure of a dimethyl-arginine-MePCE peptide would be much more informative.

Crystals of JMJD6 took more than one year to grow, we even had a hard time to repeat this crystallization condition in the past year, it will be our future focus to get complex structures of JMJD6 with different substrates.

> 2\) The finding that most inhibitory components of the 7SK snRNP including MePCE itself are positively regulated by JMJD6 via an unknown mechanism is confusing (Figure 2A). This introduces a huge confounding element that remains unexplained but could have direct influence on the phenotype in Figure 4.

As we mentioned in the context, it is a big puzzle for us to interpret the result so far since we did not see any change of mRNA in the JMJD6 knockout cell line. It must be some translational issue. It is one of our next question to address. For Figure 4, we have added more convincing data now, see below.

> 3\) The model in Figure 4 does not mention Mope cleavage and is exclusively composed of elements from other publications featuring the recruitment of JMJD6 via RNA and binding to BRD4. No experimental data in the manuscript supports this model. In fact, this model can function without MePCE cleavage.

We have added new data to support the Figure 4 model, in which we show the relative position of JMJD6 and how it is recruited by RNA and BRD4. As you can see from Figure 4A, knockout of JMJD6 lead to drastic loss of active Pol II (Pol II Ser2p-CTD) whereas JMJD6 overexpression leads to a drastic increase in active Pol II. The newly added Figure 4B showed that Pol II Ser2p-CTD dropped \~50% in three repeats when JMJD6 is knocked out, whereas Pol II Ser2p-CTD is increased to \~150% when JMJD6 is overexpressed. Newly added Figure 4C showed that MePCE knockout dramatically increases the content of active Pol II (Pol II Ser2p-CTD). These new data confirm that both JMJD6 and MePCE are closely related to the activities of Pol II.

We have added mutation data to support the model of Figure 3G now. Our new collaborator (author added), Dr. Yuhua Xue's group has generated MePCE knockout 293T cell line as demonstrated in Figure 3H. When we introduced wild type of MePCE into this MePCE KO cell line (Figure 3I), we saw a degraded band (Figure 3I, left lane), but not the mutant MePCE with --RRRR- to --AAAA- change (Figure 3I, right lane). On the other hand, it remains true that when the two versions are introduced to the JMJD6 overexpression cell line with JMJD6 knockout background (Figure 3J), wild type MePCE has two bands (Figure 3J, left), while mutant MePCE has a dominated band but a weak low molecular band. We believe that the high content of overexpressed JMJD6 could lead to weak non-specific cut at the mutant site. in vitro data is shown in Figure 3---figure supplement 2B (native MePCE), and Figure 3---figure supplement 2C (mutant MePCE).

*4) The recognition and cleavage site mapping in MePCE is nice but would be even nicer if supported by mutagenesis of full-length MePCE and testing* in vitro *and after overexpression in cells.*

Please see our response to comment \#3 above.

> 5\) The S2P phenotype in Figure 4 is not the cleanest and should be quantified in multiple experiments. No evidence links this phenotype to the described cleavage of MePCE. In fact, a recent paper by Shelton et al., 2018 questions that MePCE is indeed part of the inhibitory 7SK snRNP but activates P-TEFb in a BRD4-independent manner. This paper should be discussed and the finding should be linked to MePCE cleavage, i.e. by looking at 7SK snRNP large complex levels in the JMJD6 KO cells.

We have added new data in Figure 4, three repeats showed the drastic dropping of active Pol II (\~50%,Pol II Ser2p-CTD) when JMJD6 is knocked out, whereas a drastic increase of active Pol II (\~150%,Pol II Ser2p-CTD) is observed when JMJD6 is overexpressed (Figure 4B). At the same time, knockout of MePCE just works opposite and dramatically increase the content of active Pol II in an 293T MePCE knockout cell line (Figure 4C). All these new data support our model of the role of JMJD6 in helping BRD4 to recruit CDK9 to Pol II (Figure 4D).

There is an interesting finding showing an alternative or free form of MePCE that could recruit CDK9 directly in Shelton et al.'s 2018 report. This form may work on a small number of gene targets as the authors mentioned, but overall MePCE should play an inhibitory role on CDK9. A recent nonsense mutant in a human disease, which increase the activity of CDK9 or Pol II, also support this general role of MePCE (Schneeberger et al., 2019). Both are cited in our revision now. Of interest, Shelton et al., found that CDK9 interacts with the N-terminal domain of MePCE (residues 1-400), it is possible that MePCE acts as an anchor to help 7SK snRNP to fast CDK9. We found that there is a similar cutting site around residues 363-366 (-RKRRR-) compared to our identified site around residues 167-172 (-KRRRR-) though we did not detect fragments cut from this site from our in vitro experiments so far, this may be an interest topic needing further investigation. We discuss it in the revised version now. The N-terminal portion of MePCE is glycine rich, which makes it a big challenge for expression and characterization.

The effect of JMJD6 on stability of 7SK snRNP was very well characterized by Drs. Michael Rosefeld and Wei Liu's groups (Liu et al., 2013). They found that JMJD6 disrupts the 7SK snRNP complex, we have discussed it in the context.

\[Editors' note: what follows is the authors' response to the second round of review.\]

> Thank you for resubmitting your work entitled \"JMJD6 Cleaves MePCE to Release P-TEFb\" for further consideration by eLife. Your revised article has been reviewed by two peer reviewers, including Zhiguo Zhang as the Reviewing Editor and Reviewer \#1, and the evaluation has been overseen by Jessica Tyler as the Senior Editor.
>
> The manuscript has been improved but there are some remaining issues that need to be addressed before acceptance, as outlined below:
>
> 1\) Please edit some minor writing issues.

We have edited the manuscript very carefully to reduce the spelling, grammar, and others.

> 2\) Please provide statistical analysis for Figure 4B and include MeCPE in their model in Figure 4D (as you are missing the point of the paper by not highlighting the main finding -\> JMJD6 cleaves MeCPE and activates P-TEFb in their model.)

Statistical analysis for Figure 4B has been provided and is described in details in the "Materials and methods"/"Quantification of Pol II Ser2p-CTD" section and figure legend. Figure 4D is newly added to highlight the model of JMJD6 cleaving MePCE in the context of 7SK snRNP disruption and P-TEFb release, as well as provide further insight via a surface charge model of JMJD6 and it's known interactions with BRD4 and ssRNA, in accordance with reports from past publications.

[^1]: These authors contributed equally to this work.
